Immediate and sustained efficacy of nemolizumab in chronic pruritus of unknown origin
Shota Nakayama
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Search for more papers by this authorSatoru Yonekura
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Search for more papers by this authorCorresponding Author
Saeko Nakajima
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan
Correspondence
Saeko Nakajima, Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Email: [email protected]
Search for more papers by this authorKenji Kabashima
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Search for more papers by this authorShota Nakayama
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Search for more papers by this authorSatoru Yonekura
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Search for more papers by this authorCorresponding Author
Saeko Nakajima
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan
Correspondence
Saeko Nakajima, Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Email: [email protected]
Search for more papers by this authorKenji Kabashima
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Search for more papers by this author
REFERENCES
- 1Kim BS, Berger TG, Yosipovitch G. Chronic pruritus of unknown origin (CPUO): Uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment. Am Acad Dermatol. 2019; 81: 1223–1224.
- 2Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020; 383: 141–150.
- 3Jeon J, Wang F, Badic A, Kim BS. Treatment of patients with chronic pruritus of unknown origin with dupilumab. J Dermatolog Treat. 2022; 33: 1754–1757.
- 4Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017; 171: 217–228.
- 5Salao K, Sawanyawisuth K, Winaikosol K, Choonhakarn C, Chaowattanapanit S. Interleukin-31 and chronic pruritus of unknown origin. Biomark Insights. 2020; 15:940712.
